Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease
-
摘要: 高钾血症是慢性肾脏病常见的并发症，轻度的高钾血症会影响神经-肌肉系统的兴奋性，导致患者出现心律失常、肌无力、酸中毒等临床表现；重度的高钾血症会引起心脏骤停、呼吸衰竭等严重并发症。本研究对慢性肾脏病高钾血症的发病机制、危害、治疗现状及进展进行综述。Abstract: hyperkalemia is a common complication of chronic kidney disease.Mild hyperkalemia can affect the excitability of neuromuscular system and induce arrhythmia, myasthenia, acidosis and other clinical manifestations.Severe hyperkalemia can cause cardiac arrest, respiratory failure and other severe complications.This study reviewed the pathogenesis, damage, treatment status and progress of hyperkalemia in chronic kidney disease.
-
-
[1] LV J C, ZHANG L X. Prevalence and disease burden of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 3-15. http://www.nature.com/articles/s41598-019-46857-7
[2] ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6
[3] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组, 高翔, 梅长林. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1): 28-34. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201701008.htm [4] 葛均波, 徐永健, 王辰. 内科学[M]. 9版. 北京: 人民卫生出版社, 2018: 774-776. [5] KASHIHARA N, KOHSAKA S, KANDA E, et al. Hyperkalemia in real-world patients under continuous medical care in Japan[J]. Kidney Int Rep, 2019, 4(9): 1248-1260. doi: 10.1016/j.ekir.2019.05.018
[6] 余仁欢. 慢性肾脏病高钾血症的防治[A]. 中国中西医结合学会肾脏疾病专业委员会. 中国中西医结合学会肾脏疾病专业委员会2018年学术年会专题讲座汇编[C]. 中国中西医结合学会肾脏疾病专业委员会: 中国中西医结合学会, 2018: 2. [7] 苏彩虹, 谢慧敏, 张云芳, 等. 慢性肾脏病合并高钾血症的原因分析[J]. 国际移植与血液净化杂志, 2019, 17(3): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMGY201802010.htm [8] CLASE C M, CARRERO J J, ELLISON D H, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(1): 42-61. doi: 10.1016/j.kint.2019.09.018
[9] 李莹. 血钾异常与慢性肾衰竭患者神经精神症状的临床分析[J]. 现代中西医结合杂志, 2010, 19(24): 3061-3062. doi: 10.3969/j.issn.1008-8849.2010.24.036 [10] 袁发焕. 慢性肾衰竭高钾血症的预防与处理[J]. 中国中西医结合肾病杂志, 2013, 14(8): 659-662. doi: 10.3969/j.issn.1009-587X.2013.08.001 [11] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志, 2020, 36(10): 781-792. doi: 10.3760/cma.j.cn441217-20200721-00139 [12] COWAN A C J, GHARIB E G, WEIR M A. Advances in the management of hyperkalemia in chronic kidney disease[J]. Curr Opin Nephrol Hypertens, 2017, 26(3): 235-239. doi: 10.1097/MNH.0000000000000320
[13] 李桂明. 钾离子与麻醉[J]. 中国伤残医学, 2014, 22(3): 281-282. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYZ201403282.htm [14] 陈孝平, 汪建平, 赵继宗. 外科学[M]. 9版. 北京: 人民卫生出版社, 2018: 16-17. [15] BIANCHI S, AUCELLA F, DE NICOLA L, et al. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology[J]. J Nephrol, 2019, 32(4): 499-516. doi: 10.1007/s40620-019-00617-y
[16] COLBERT G B, PATEL D, LERMA E V. Patiromer for the treatment of hyperkalemia[J]. Expert Rev Clin Pharmacol, 2020, 13(6): 563-570. doi: 10.1080/17512433.2020.1774363
[17] WEIR M R, BAKRIS G L, BUSHINSKY D A, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors[J]. N Engl J Med, 2015, 372(3): 211-221. doi: 10.1056/NEJMoa1410853
[18] BAKRIS G L, PITT B, WEIR M R, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial[J]. JAMA, 2015, 314(2): 151-161. doi: 10.1001/jama.2015.7446
[19] RAFIQUE Z, LIU M, STAGGERS K A, et al. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study[J]. Acad Emerg Med, 2020, 27(1): 54-60. doi: 10.1111/acem.13868
[20] RIZK J, QUAN D, GABARDI S, et al. Novel approaches to management of hyperkalaemia in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2021, 30(1): 27-37. doi: 10.1097/MNH.0000000000000657
[21] STAVROS F, YANG A, LEON A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap[J]. PLoS One, 2014, 9(12): e114686. doi: 10.1371/journal.pone.0114686
[22] PACKHAM D K, RASMUSSEN H S, LAVIN P T, et al. Sodium zirconium cyclosilicate in hyperkalemia[J]. N Engl J Med, 2015, 372(3): 222-231. doi: 10.1056/NEJMoa1411487
[23] KOSIBOROD M, RASMUSSEN H S, LAVIN P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial[J]. JAMA, 2014, 312(21): 2223-2233. doi: 10.1001/jama.2014.15688
[24] ROGER S D, SPINOWITZ B S, LERMA E V, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of harmonize[J]. Am J Nephrol, 2019, 50(6): 473-480. doi: 10.1159/000504078
[25] SPINOWITZ B S, FISHBANE S, PERGOLA P E, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study[J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809. doi: 10.2215/CJN.12651018
[26] KASHIHARA N, NISHIO T, OSONOI T, et al. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose: response, phase 2/3 study[J]. Clin Exp Nephrol, 2020, 24(12): 1144-1153. doi: 10.1007/s10157-020-01937-1
[27] PEACOCK W F, RAFIQUE Z, VISHNEVSKIY K, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase Ⅱ, randomized, double-blind, placebo-controlled study (energize)[J]. Acad Emerg Med, 2020, 27(6): 475-486. doi: 10.1111/acem.13954
[28] 边佳明, 左力, 赵厚宇, 等. 中国门诊患者高钾血症分布及诊疗现状的流行病学研究[J]. 中国血液净化, 2020, 19(11): 726-729, 746. doi: 10.3969/j.issn.1671-4091.2020.11.002 -
期刊类型引用(3)
1. 王永庆，蔡学礼，黄良通. 神经介入联合小剂量替罗非班在缺血性卒中患者中的应用. 中国医师杂志. 2024(09): 1423-1426 . 
百度学术
2. 赵建彬，赵玮康. 双负荷剂量氯吡格雷联合阿司匹林治疗急性脑梗死的疗效研究. 中国合理用药探索. 2023(09): 73-77 . 百度学术
3. 陈莉，钟华. 阿替普酶静脉溶栓联合替罗非班及双抗治疗内囊预警综合征1例报道. 心脑血管病防治. 2022(05): 102-104 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 612
- HTML全文浏览量: 282
- PDF下载量: 64
- 被引次数: 3
下载:
苏公网安备 32100302010246号
